Reduce severe side effects of fluoropyrimidine (e.g. 5-FU) treatment by DPYD genotyping.

Fluoropyrimidines are widely used for the treatment of various solid tumors. ViennaLab assays identify the most common variants in the dihydropyrimidine dehydrogenase (DPYD) gene with therapeutic relevance for fluoropyrimidine treatment.

 

PGX-5FU

 

  • Fluoropyrimidines (5-Fluorouracil, Capecitabine and Tegafur) are frequently used in cancer therapy. However, some patients develop severe treatment-related toxicity.
  • A part of fluoropyrimidine-related toxicity arises due to impaired activity of the key metabolic enzyme dihydropyrimidine dehydrogenase (DPD) caused by genetic variants in the DPYD gene.
  • CPIC Guidelines recommend DPYD genotype-guided fluoropyrimidine dosing to reduce the risk of toxicity in cancer patients.

Link to CPIC Guidelines

 

ProductREFUnit SizeIFUBrochure
PGX-5FU StripAssay®4-72020 tests

PDF

PDF